User:Mr. Ibrahem/Eslicarbazepine acetate

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Eslicarbazepine acetate
Clinical data
Trade namesAptiom, Zebinix, Exalief, others
AHFS/Drugs.comMonograph
License data
Pregnancy
category
Routes of
administration		By mouth (tablets)
Drug classAnticonvulsant
Legal status
Legal status
  • AU: S4 (Prescription only)[1]
  • US: ℞-only[2]
  • EU: Rx-only[3]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding~30%[4]
MetabolismUGT (?)
MetabolitesEslicarbazepine (active), glucuronides (inactive), etc.
Elimination half-life10–20 hours
Excretion~90% renal
Identifiers
  • (S)-10-Acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide
Chemical and physical data
FormulaC17H16N2O3
Molar mass296.326 g·mol−1
3D model (JSmol)
  • CC(=O)OC2Cc1ccccc1N(C(N)=O)c3c2cccc3
  • InChI=1S/C17H16N2O3/c1-11(20)22-16-10-12-6-2-4-8-14(12)19(17(18)21)15-9-5-3-7-13(15)16/h2-9,16H,10H2,1H3,(H2,18,21)/t16-/m0/s1
  • Key:QIALRBLEEWJACW-INIZCTEOSA-N

Eslicarbazepine acetate (ESL), sold under the brand names Aptiom and Zebinix among others, is a medication used to treat epilepsy with focal-onset seizures.[3][2] It is taken by mouth.[2] It may be used along or with other anti seizure medications.[5]

Common side effects include dizziness, sleepiness, nausea, headache, double vision, tiredness, poor coordination, blurry vision, and tremor.[2] Other side effects may include suicide, anaphylaxis, low sodium, and liver problems.[2] Safety in pregnancy is unclear.[6] It is a prodrug to (S)-(+)-licarbazepine, similarly to oxcarbazepine; and is beleived to work by inhibiting sodium channels.[6]

Eslicarbazepine acetate was approved for medical use in Europe in 2009 and the United States in 2013.[6][3] In the United Kingdom a dose of 400 mg per day for a month costs the NHS about £68 as of 2021.[5] In the United States this amount costs about 1,050 USD.[7]

References[edit]

  1. ^ a b "Zebinix". Therapeutic Goods Administration (TGA). 9 June 2021. Archived from the original on 6 September 2021. Retrieved 6 September 2021.
  2. ^ a b c d e f "Aptiom- eslicarbazepine acetate tablet Aptiom- eslicarbazepine acetate kit". DailyMed. Archived from the original on 27 March 2021. Retrieved 21 January 2021.
  3. ^ a b c d "Zebinix EPAR". European Medicines Agency (EMA). Archived from the original on 5 March 2021. Retrieved 21 January 2021.
  4. ^ Dinnendahl V, Fricke U, eds. (2011). Arzneistoff-Profile (in German). Vol. 4 (25 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3.
  5. ^ a b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 330. ISBN 978-0857114105.
  6. ^ a b c "Eslicarbazepine Monograph for Professionals". Drugs.com. Archived from the original on 18 January 2021. Retrieved 16 December 2021.
  7. ^ "Eslicarbazepine Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 16 December 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Eslicarbazepine_acetate&oldid=1217996767"